Tirzepatide ZPHC — 150 mg (5 vials × 30 mg)

Tirzepatide — ZPHC
5 lyophilised vials × 30 mg (total 150 mg) + sterile diluent

• Dual incretin agonist: activates GLP-1 & GIP receptors for powerful appetite suppression and improved metabolic control.
• Advanced weight-management: researched for reductions in caloric intake, improved glycaemic response and enhanced fat-loss outcomes.
• High-purity formulation: ≥ 98.9% purity (HPLC); produced under GMP & ISO 17034:2016 with ZPHC scratch-code verification.
• Reconstitution: mix each vial with sterile diluent provided; swirl gently until dissolved. Store at 2–8 °C.
• For research use only: analytical reference material; not intended for therapeutic or human use.
• Cold-chain packed • tamper-evident vials • discreet, tracked worldwide delivery.